Calamos Advisors’s Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 TRCA.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-83,333
Closed -$6.26K 1018
2023
Q3
$6.26K Hold
83,333
﹤0.01% 895
2023
Q2
$4.56K Hold
83,333
﹤0.01% 967
2023
Q1
$7.08K Hold
83,333
﹤0.01% 1079
2022
Q4
$2.51K Hold
83,333
﹤0.01% 1184
2022
Q3
$5K Buy
+83,333
New +$6.82K ﹤0.01% 1212

Calamos Advisors's TRCA.WS Position: Q4 2023 in Review

Calamos Advisors sold out of Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 (TRCA.WS) in Q4 2023, closing a stake of 83,333 shares — an estimated $6.26K sold.

Calamos Advisors first reported a position in TRCA.WS in Q3 2022 and held it in 5 quarters. The position peaked at $7.08K in Q1 2023. 0 funds tracked by Wall St. Rank hold TRCA.WS as of Q4 2023.

  • Calamos Advisors reported no remaining Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position as of Q4 2023 after selling out during the quarter.
  • Calamos Advisors sold 83,333 Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 shares in Q4 2023, an estimated $6.26K.
  • Calamos Advisors first reported a position in Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 in Q3 2022 and held it in 5 quarters.
  • Calamos Advisors's Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position peaked at $7.08K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Twin Ridge Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 as of Q4 2023.

Based on Calamos Advisors's 13F filing for Q4 2023, filed 31 Jan 2024.